PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

about

Managing cognition in progressive supranuclear palsy.

P2860

Q39017916-14DF63F3-9EF6-4714-BDB4-76E2909AE929

P2860

PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

Item

http://www.wikidata.org/entity/Q38861792

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

PROSPERA: a randomized, contro ...... rogressive supranuclear palsy.

@en

type

Item

label

PROSPERA: a randomized, contro ...... rogressive supranuclear palsy.

@en

prefLabel

PROSPERA: a randomized, contro ...... rogressive supranuclear palsy.

@en

P1476

PROSPERA: a randomized, contro ...... rogressive supranuclear palsy.

@en

P2093

Alexander Crispin

http://www.w3.org/2001/XMLSchema#string

Andreas Zwergal

http://www.w3.org/2001/XMLSchema#string

Georg Nuebling

http://www.w3.org/2001/XMLSchema#string

Mira Hensler

http://www.w3.org/2001/XMLSchema#string

Sabine Paul

http://www.w3.org/2001/XMLSchema#string

Stefan Lorenzl

http://www.w3.org/2001/XMLSchema#string

P2860

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

New insights into progressive supranuclear palsy.

Progressive supranuclear palsy: clinical features, pathophysiology and management.

Depression rating scales in Parkinson's disease: critique and recommendations.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.

Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria.

Rate of decline in progressive supranuclear palsy.

P2888

s00415-016-8169-1

P304

1565-1574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-016-8169-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

263

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048455242

http://www.w3.org/2001/XMLSchema#string

P698

27230855

http://www.w3.org/2001/XMLSchema#string

PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

about

P2860

P2860

PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698